Comparison of the in Vivo Activities of Garenoxacin and Levofloxacin in a Murine Model of Pneumonia by Mixed-Infection with Streptococcus pneumoniae and Parvimonas micra.
Animals
Anti-Bacterial Agents
/ therapeutic use
Coinfection
/ drug therapy
Disease Models, Animal
Female
Firmicutes
Fluoroquinolones
/ therapeutic use
Levofloxacin
/ therapeutic use
Mice, Inbred ICR
Neutropenia
Pneumonia, Bacterial
/ drug therapy
Specific Pathogen-Free Organisms
Streptococcus pneumoniae
garenoxacin
in vivo
levofloxacin
pneumonia
Journal
Japanese journal of infectious diseases
ISSN: 1884-2836
Titre abrégé: Jpn J Infect Dis
Pays: Japan
ID NLM: 100893704
Informations de publication
Date de publication:
21 Nov 2019
21 Nov 2019
Historique:
pubmed:
2
8
2019
medline:
15
4
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
Community-acquired pneumonia (CAP) can involve mixed-species bacterial infection. However, few studies have investigated antimicrobial efficacy in the treatment of mixed species infections. This study aimed to compare the in vivo antimicrobial activity of garenoxacin (GRNX) and levofloxacin (LVFX) against Streptococcus pneumoniae and Parvimonas micra in a murine model of mixed species bacterial pneumonia. S. pneumoniae D-6888 and P. micra No. 242 were used in this study. Antimicrobial activity toward each isolate was calculated as the change in bacterial count in the lungs (Δlog
Identifiants
pubmed: 31366860
doi: 10.7883/yoken.JJID.2019.109
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fluoroquinolones
0
Levofloxacin
6GNT3Y5LMF
garenoxacin
V72H9867WB
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM